soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Scorecard: Semaglutide cardiovascular outcomes align more

These data are consistent with data from prior large trials of the injectable formulation, SELECT (subcutaneous semaglutide 2.4 mg in obesity without diabetes) reported an HR of 0.80 [40] and SUSTAIN 6 (subcutaneous semaglutide 0.5 mg /1.0 mg in T2DM) [41] which showed reduced MACE

In some places, the inner and outer membranes of the nucleus are separated (red arrow number 6)

Christie DA, Kirchhof MG, Vardhana S, Dustin ML, Madrenas J

Age- and sex-specific prevalence of diabetes associated with diseases of the exocrine pancreas: a population-based study

Which is better for very pale skin: Melanotan 1 or Melanotan 2

These findings remain preliminary but suggest avenues for future investigation